On May 3, 2019, the Food and Drug Administration approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.http://bit.ly/2ZZ0vi1
What more needs to be said? More ADCs going to more patients with more indications is an unequivocal win for the ADC industry.
Here is Fierces Take : http://bit.ly/2ZZDknQ
Post a Comment